Silencing a Cancer Driver: Locked Nucleic Acid-Modified siRNA Treatment Provides a New Path for FXR1-Targeted Cancer Therapy
RNA-binding proteins (RBPs) are key drivers of cancer but remain largely undruggable. Using nanoparticle-delivered LNA-siRNA, we achieved selective inhibition of FXR1, demonstrating the feasibility of precision RBP targeting in preclinical cancer models.
